First-in-Human trial tests 'Living Drug' for untreatable progressive MS
NCT ID NCT06138132
Summary
This is an early safety study testing a new, personalized cell therapy called KYV-101 for adults with progressive forms of multiple sclerosis (MS) that are worsening and have no approved treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target harmful B cells thought to drive MS, and infuse them back. The main goal is to check the safety of different doses and see if the treatment can reduce disability and slow brain volume loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Multiple Sclerosis Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.